The increase in price target by Truist Securities suggests an improved outlook on Zimmer Biomet's stock value, which could lead to increased investor confidence and a potential short-term rise in the stock price. The Hold rating indicates that the analyst sees the company as fairly valued at the moment, but the raised target implies expectations of growth or positive performance.